Table 2.

Drug treatment strategy in SQTS patients (of Table 1 ) and side effects.

Author	(El-Battrawy et al., 2018)	(Bun et al., 2012)	(Mazzanti et al., 2017)	(Guistetto et al., 2011)	(Villafane et al., 2013)	(Suzuki et al., 2014)	(Guistetto et al., 2015)
Patients on antiarrhythmic drugs on discharge, n (%)	8	1	17	22	10	1	3
Age, median (years)	34	28	29	26	15	10	21
HQ, n	6	1	17	22	5	1	3
Flecainide, n	0	0	0	0	1	0	0
Sotalol, n	0	0	0	3	0	0	2
Sotalol plus propafenone, n	0	0	0	0	1	0	0
Propafenone plus digoxin, n	0	0	0	0	1	0	0
Dofetilide plus digoxin, n	0	0	0	0	1	0	0
Disopyramide, n	0	0	0	3	0	0	0
Bisoprolol, n	2	0	0	0	0	0	0
Amiodarone, n	0	0	0	1	0	0	0
Amiodarone plus metoprolol	0	0	0	1	0	0	0
Dosage HQ (mg) daily, mean	916.66	600	584	870	—	20 mg/kg	666.66
Side effects of HQ and stopped treatment	n = 2 poor compliance	none	n = 2 gastrointestinal intolerance	n = 6 poor compliance, n = 2 no effect on QTc, n = 2 gastrointestinal intolerance	—	none
QTc before HQ (ms)	318 ± 29 (n = 6)	320	331 ± 3	307 ± 20 |(n = 18)	304 ± 42 (n = 25)	283	332 ± 23
QTc after HQ (ms)	404 ± 46 (n = 6)	383	391 ± 9	384 ± 39 (n = 18)	—	341	378 ± 33
EPU before HQ	n = 3 inducible arrhythmias	NA	NA	n = 8 EPU done before and after drug	—		n = 2 short atrial and ventricular refractory periods
EPU after HQ	n = 3 no inducible arrhythmias anymore	NA	NA	n = 8 none inducible VF	—		NA
Follow-up (months) days	4860	180	2130	1920	2130	—	708

—, not documented; NA, not available.